Georgia is expanding its medical funding program and will fully cover the cost of the drug Jakavi for patients with severe complications after bone marrow transplantation.
This refers to the condition known as GVHD ("graft-versus-host disease"), where donor cells begin to attack the patient's body. In severe, steroid-resistant cases, treatment requires expensive therapy, which patients previously paid for themselves.
As reported by the Ministry of Health, bone marrow transplantation is already funded by the state both domestically and abroad, but now the program is expanding to include postoperative treatment of complications. The drug Jakavi will be provided free of charge to all patients with oncohematological diagnoses who develop a severe form of GVHD.
The program will cover citizens of the country, children under 18, as well as holders of neutral documents, refugees, and individuals with humanitarian status. Residents of regions with special administrative status, registered under Georgian law, are also included.